Browsing Tag
Type 2 Diabetes
44 posts
Insulet Omnipod 6 data puts PODD back in focus as automated insulin delivery moves toward type 2 diabetes
Read how Insulet Omnipod 6 data could reshape automated insulin delivery, type 2 diabetes care and PODD stock sentiment. Find out what changes next in 2026.
DexCom (DXCM) gains strategic evidence edge as CONNECT study targets broader diabetes market
Find out how DexCom’s CONNECT study could expand CGM use in non-insulin Type 2 diabetes and reshape DXCM’s growth outlook.
Glenmark Pharmaceuticals (NSE: GLENMARK) launches GLIPIQ semaglutide in India at Rs 325 a week as generic GLP-1 era starts
Glenmark Pharmaceuticals launches GLIPIQ semaglutide in India from Rs 325 a week. Analysis of pricing, competition, and what it means for GLP-1 access. Read more.
Lifeward (Nasdaq: LFWD) bets on oral insulin platform to escape medical device treadmill
Lifeward (LFWD) posts full-year 2025 revenue of $22M, down 14%, as shareholders approve the Oramed POD platform deal. Here is what it means for LFWD investors. Read more.
Novo Nordisk’s amycretin delivers 14.5% weight loss in type 2 diabetes trial: A dual-agonist breakthrough?
Novo Nordisk’s amycretin delivers up to 14.5% weight loss in type 2 diabetes trial. Explore the trial data and what’s next in the GLP‑1 drug race.
Innovent Biologics hits 20% weight loss in Phase 3: Will mazdutide become China’s Ozempic?
Mazdutide 9 mg achieves 20.08% weight loss in pivotal Chinese Phase 3 study. Learn what this means for Innovent Biologics’ NDA plans and obesity treatment.
Lilly’s orforglipron proves oral GLP-1 power with impressive Phase 3 diabetes data
Find out how Eli Lilly’s oral GLP-1 drug orforglipron excelled in Phase 3 trials and could become a foundational therapy for type 2 diabetes.
Biomea Fusion reports positive 52-week phase II results showing non-chronic icovamenib treatment benefits in type 2 diabetes
Find out how Biomea Fusion’s 52-week phase II results point to a regenerative, non-chronic path for type 2 diabetes treatment.
Metabolics Pharma’s ENT-03 shows promising Phase 1a data in obese and type 2 diabetic patients at ADA 2025
Metabolics Pharma’s ENT-03 shows Phase 1a success in obese and diabetic subjects, with plans for Phase 1b in late 2025. Learn about its brain-based mechanism.
Semaglutide shows significant vascular benefits in PAD patients with type 2 diabetes, STRIDE trial confirms
Semaglutide improves walking capacity and reduces disease progression in PAD patients with type 2 diabetes, STRIDE trial results reveal at ADA 2025.